Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jan 24;7(8):9084–9101. doi: 10.18632/oncotarget.7000

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © 2016 Hou et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

AML patients were grouped according to scoring system based on SF mutation and 10 other prognostic markers (CEBPA^{double-mutation}, NPM1/FLT3-ITD, IDH2, TP53, WT1, RUNX1 and DNMT3A mutations, cytogenetics, age and WBC counts at diagnosis). A score of -3 was assigned for NPM1⁺/FLT3-ITD⁻ and -2 for CEBPA^{double-mutation} and IDH2 mutation whereas a score of +3 for TP53 mutation and +2 for other factors associated with an adverse outcome (SF, DNMT3A, WT1 and RUNX1 mutations, older age, higher WBC counts at diagnosis and unfavorable cytogenetics). The algebraic summation of these scores of each patient was the final score. This score system divided the AML patients into five groups with different clinical outcomes (P < 0.001 for both OS and DFS). The 12 patients without chromosome data were not included in the analysis.

AML patients were grouped according to scoring system based on SF mutation and 10 other prognostic markers (CEBPA^{double-mutation}, NPM1/FLT3-ITD, IDH2, TP53, WT1, RUNX1 and DNMT3A mutations, cytogenetics, age and WBC counts at diagnosis). A score of -3 was assigned for NPM1⁺/FLT3-ITD⁻ and -2 for CEBPA^{double-mutation} and IDH2 mutation whereas a score of +3 for TP53 mutation and +2 for other factors associated with an adverse outcome (SF, DNMT3A, WT1 and RUNX1 mutations, older age, higher WBC counts at diagnosis and unfavorable cytogenetics). The algebraic summation of these scores of each patient was the final score. This score system divided the AML patients into five groups with different clinical outcomes (P < 0.001 for both OS and DFS). The 12 patients without chromosome data were not included in the analysis.